Default Category
-
Dr. Reddy's Laboratories (B)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08M065-EStrategyThis supplement to Dr. Reddy's Laboratories (A), product # 9B08M064, looks at the two years post-acquisition and examines a major risk which, as it unfolded, brought the viability of the business model into question.Starting at €5.74
-
Dr. Reddy's Laboratories (A)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08M064-EStrategyDr. Reddy's Laboratories (Dr. Reddy's), a large pharmaceutical company in India, is trying to acquire the fourth largest generics manufacturer in Germany. Dr. Reddy's quoted $570 million in a competitive bidding situation. The company's chief negotiator is getting ready to close the deal if selected. Students will examine the issues for the chief negotiator, such as: is the price right, is the fit strategic, will the acquisition add value, how ca...Starting at €8.20
-
Telefónica en Alemania (B). La compra de E-Plus
Lucas Chinchilla, Pablo, García de Castro, Antonio.,Lucas Tomás, Jose LuisCase IIST-DGI-253StrategyTras la salida a Bolsa de Telefónica Alemania en 2012, la compañía inició su andadura como una compañía cotizada. Poco tiempo después Telefónica Alemania anunciaba el acuerdo para adquirir E-Plus, la filial alemana de la compañía de telecomunicaciones holandesa KPN, con el objetivo de crear la principal compañía de telecomunicaciones del país. E-Plus era la mayor filial extranjera de KPN y el tercer operador de telefonía móvil en Alemania. ...Starting at €5.74
-
Telefónica en Alemania (A). La salida a bolsa
Lucas Chinchilla, Pablo, García de Castro, Antonio.,Lucas Tomás, Jose LuisCase IIST-DGI-252StrategyEn mayo de 2012 el Consejo de Administración del Grupo Telefónica tomó la decisión “gestionar de manera proactiva la cartera de activos de la Compañía”, lo que incluía entre otras medidas iniciar el proceso de salida a Bolsa de su filial en Alemania. Por entonces la zona euro vivía las turbulencias de una profunda crisis financiera y económica, en aquel momento de consecuencias impredecibles. Telefónica Alemania era uno de los operadores de telec...Starting at €8.20
-
Dr. Reddy's Laboratories (A) (Spanish version)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08MS64StrategyDr. Reddy's Laboratories (Dr. Reddy's), a large pharmaceutical company in India, is trying to acquire the fourth largest generics manufacturer in Germany. Dr. Reddy's quoted $570 million in a competitive bidding situation. The company's chief negotiator is getting ready to close the deal if selected. Students will examine the issues for the chief negotiator, such as: is the price right, is the fit strategic, will the acquisition add value, how ca...Starting at €8.20
-
Dr. Reddy's Laboratories (B) (Spanish version)
Jean-Louis Schaan; Ramasastry ChandrasekharCase IVEY-9B08MS65StrategyThis supplement to Dr. Reddy's Laboratories (A), product # 9B08M064, looks at the two years post-acquisition and examines a major risk which, as it unfolded, brought the viability of the business model into question.Starting at €5.74
-
Schibsted (A): Should We Launch 20 Minutes
Jean-Louis Schaan; Jordan MitchellCase IVEY-9B07M019-EStrategyThe executive vice-president of newspapers for Schibsted was about to meet with his colleagues to discuss the company's plan to release an internally developed free daily newspaper concept called 20 Minutes. Over the past couple of years, Schibsted's executive team had kept a watchful eye on the free newspaper industry, which was enjoying tremendous popularity. Earlier in the year, Schibsted had launched Avis 1, a free paper with direct delivery ...Starting at €8.20